Skip to main content
. Author manuscript; available in PMC: 2018 Mar 15.
Published in final edited form as: Eur J Pharmacol. 2017 Feb 10;799:128–134. doi: 10.1016/j.ejphar.2017.02.016

Fig 1. IL-10 is involved in C21 mediated neuroprotection after ischemia/reperfusion injury in vivo.

Fig 1

Fig 1

A: Schematic diagram representing the study outline and treatment groups. Wistar rats were subjected to 3 h MCAO using the suture model followed by reperfusion for 21 h. Treatments were administered i.p. at reperfusion in separate syringes. Animals were assigned to one of four treatment groups in a 2X2 study design as outlined in the table.

B: Representative TTC stained brain sections and quantification of infarct size from the four treatment groups. C21 treatment reduced infarct size at 24 h after 3 h MCAO. Co-treatment with anti-IL-10 neutralizing antibody abrogated the neuroprotective effect of C21 treatment. N=7–9 per group. *P<0.05 vs other groups (Two-way ANOVA).